

**STATE OF CONNECTICUT**  
DEPARTMENT OF PUBLIC HEALTH

Manisha Juthani, MD  
Commissioner



Ned Lamont  
Governor  
Susan Bysiewicz  
Lt. Governor

Universal cCMV Screening Working Group  
Approved Meeting Minutes  
Monday, April 1, 2024  
11:45 AM – 1 PM

**Working Group Members**

Present: Jody Terranova, DO, MPA FAAP (Chair), Nancy A. Louis, MD, FAAP, Ashley C. Howard, DO, FAAP, Thomas Murray, MD, PhD, FAAP, Carlos R. Oliveira, MD, PhD, Scott Schoem, MD, MBA, FAAP, Jafar H. Razeq, Ph.D., HCLD/PHLD (ABB), Adrienne Manning, Marie Burlette, RN, BSN, MPH, John Lamb, and Amaka Atuegbu

Others present: Commissioner Manisha Juthani, MD

Absent: Debra Ellis, RN, BSN

- I. Call to Order
  - a. The meeting was held via Teams and Dr. Terranova called the meeting to order at 11:47 AM.
- II. Approval of Minutes
  - a. Dr. Schoem moved to approve the minutes of March 14, 2023. Dr. Louis seconded the motion. The motion passed unanimously.
- III. Public comment
  - a. Commissioner Juthani, MD thanked the Working Group for their dedication and recommendations.
- IV. New Business
  - a. CT DPH presentation of comprehensive summary recommendations
    - i. Ms. Atuegbu presented the summary recommendations of the four subgroups: Treatment for Positive Asymptomatic Newborns, Lab Methodology, Planning for Implementation, and Education subgroups.
  - b. Working Group review of draft report
    - i. Dr. Razeq suggested few changes to the lab methodology subgroup section and conclusion of the report.
    - ii. Dr. Schoem asked pediatric infectious disease specialists to provide their educated guesses on potential number of cCMV-infected infants in the state, after universal screening. Dr. Schoem noted that under current targeted screening, fewer numbers of cCMV -infected infants have been

reported than previously estimated. Dr. Murray responded that number of infants who screen positive and those that require antiviral therapy would need to be considered, noting that the latter would potentially be low. Dr. Howard estimated that about 200-250 infants per year may have dried blood spot positive findings and a third of those may meet the criteria for antiviral treatment. Dr. Oliveira also shared a recent Massachusetts report on the state's expected cCMV-infected rates, symptomatic rates, and estimated costs of cCMV care.

- iii. Dr. Terranova asked the group if there are any other additional resources that will be needed to successfully implement universal cCMV screening. Ms. Burlette noted the need to specifically call-out LIMS data management support needs. Drs. Murray and Razeq also noted the need to emphasize the urgency of intervention and the need for appropriate resources.
- iv. Dr. Terranova stated the report will be updated to include background information on what cCMV is, its clinical presentation, and estimated rate of occurrence.
- v. Dr. Murray asked if CT DPH will continue to coordinate with Connecticut Children's Medical Center and Yale New Haven Children's Hospital before universal cCMV screenings begin in July 2025. Dr. Terranova assured the group that CT DPH will continue to coordinate with them and encouraged the providers to develop standard treatment guidelines to maintain consistency in addressing cCMV in the state.

V. Announcements

a. Next steps

- i. Dr. Terranova noted that the final report will be submitted to the Commissioner and the Connecticut Office of Policy and Management for review before the Commissioner presents the findings to the Connecticut General Assembly.
- ii. Dr. Terranova thanked the Working Group for all their efforts and recommendations.

VI. Adjournment

- a. Dr. Terranova adjourned the meeting at 12:32 PM.